Anixa Biosciences Inc
corporate_fare Company Profile
Anixa Biosciences Inc (NASDAQ:ANIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ANIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ANIX spans 10-Q, 8-K, 10-K, SCHEDULE 13D/A.
Recent high-impact activity:
- Fifth CAR-T Cohort Dosed; Four Ovarian Cancer Patients Survive Beyond One Year
- Anixa CAR-T Shows First Stable Disease at 3 Months in Ovarian Cancer
- Australian Patent Acceptance Expands Breast Cancer Vaccine IP to Key Market
- Anixa Biosciences Secures First Korean Patent for Breast Cancer Vaccine, Extending Protection to 2040
- Anixa Biosciences Reports Improved Q3 Net Loss of $2.52M, $13.7M Cash Extends Runway
Financial Snapshot
Short Interest & Short Volume
8.40 days to coverFINRA reported short interest of 1,628,481 shares in ANIX as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 72.8% of ANIX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.